Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Ballard P, et al. Among authors: kim dw. Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. doi: 10.1158/1078-0432.CCR-16-0399. Epub 2016 Jul 19. Clin Cancer Res. 2016. PMID: 27435396
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. Han SW, et al. Among authors: kim dw, kim ty, kim j, kim yt, kim nk, kim jh. J Clin Oncol. 2005 Apr 10;23(11):2493-501. doi: 10.1200/JCO.2005.01.388. Epub 2005 Feb 14. J Clin Oncol. 2005. PMID: 15710947 Clinical Trial.
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. Han SW, et al. Among authors: kim dw, kim ty, kim nk, kim jh. Clin Cancer Res. 2006 Apr 15;12(8):2538-44. doi: 10.1158/1078-0432.CCR-05-2845. Clin Cancer Res. 2006. PMID: 16638863
Palliative chemotherapy for pulmonary pleomorphic carcinoma.
Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS. Bae HM, et al. Among authors: kim dw, kim yw. Lung Cancer. 2007 Oct;58(1):112-5. doi: 10.1016/j.lungcan.2007.05.006. Epub 2007 Jun 18. Lung Cancer. 2007. PMID: 17574296
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ. Yi HG, et al. Among authors: kim cs, kim yj, kim hj, kim dw, kim ty. Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6. Lung Cancer. 2009. PMID: 19059670
5,331 results